backgroundnipah
viru
niv
zoonot
pathogen
caus
sever
respiratori
ill
enceph
human
emerg
malaysia
subsequ
outbreak
almost
annual
basi
sinc
part
indian
subcontin
high
case
fatal
rate
humantohuman
transmiss
widerang
reservoir
distribut
lack
licens
intervent
option
make
niv
seriou
region
potenti
global
public
health
problem
object
studi
develop
fastact
singledos
niv
vaccin
could
implement
ring
vaccin
approach
outbreak
methodsin
studi
design
new
liveattenu
vaccin
vector
base
recombin
vesicular
stomat
virus
rvsv
express
niv
glycoprotein
g
f
nucleoprotein
n
evalu
protect
efficaci
syrian
hamster
establish
niv
anim
diseas
model
character
humor
immun
respons
vaccin
hamster
use
elisa
neutral
assay
perform
serum
transfer
studi
strong
humor
immun
respons
neutral
activ
found
anim
vaccin
rvsv
express
niv
g
f
protein
vaccin
anim
neutral
antibodi
respons
complet
protect
lethal
niv
diseas
wherea
anim
vaccin
rvsv
express
niv
n
show
partial
protect
protect
niv
g
f
vaccin
anim
confer
antibodi
like
neutral
fraction
demonstr
serum
transfer
studi
protect
nvaccin
hamster
antibodydepend
indic
role
adapt
cellular
respons
protect
nipah
viru
niv
famili
paramyxovirida
genu
henipaviru
discov
caus
agent
outbreak
viral
enceph
pig
farmer
malaysia
initi
larg
outbreak
follow
smaller
nearli
annual
outbreak
bangladesh
india
diseas
human
character
respiratori
distress
andor
enceph
histopatholog
chang
lung
brain
show
multinucl
giant
cell
throughout
microvasculatur
niv
highli
pathogen
human
reach
case
fatal
rate
averag
transmiss
niv
natur
reservoir
pteropu
fruit
bat
pig
human
document
well
humantohuman
transmiss
current
approv
vaccin
therapeut
human
use
niv
infect
although
public
health
concern
region
nation
even
intern
author
widespread
campaign
vaccin
larg
percentag
atrisk
human
popul
niv
infect
current
seem
unfound
outbreak
rare
result
rel
case
focal
isol
humantohuman
transmiss
gener
confin
health
care
worker
famili
member
engag
close
contact
expos
individu
thu
rather
favor
ring
vaccin
approach
therefor
vaccin
produc
rapid
robust
immun
respons
singl
immun
potenti
periexposur
applic
emerg
vaccin
would
benefici
current
vaccin
approach
protect
niv
infect
focus
use
niv
glycoprotein
g
andor
fusion
protein
f
immunogen
variou
platform
includ
dna
vaccin
subunit
vaccin
nonrepl
vector
well
replic
vector
efficaci
previous
test
vaccin
candid
requir
prime
boost
approach
would
favor
use
emerg
situat
rapid
dissemin
outbreak
order
develop
vaccin
appropri
ring
vaccin
gener
liveattenu
recombin
vesicular
stomat
virus
rvsv
encod
individu
niv
protein
use
establish
revers
genet
system
vsv
vsv
system
use
gener
vaccin
candid
mani
diseasecaus
virus
fastact
singledos
vaccin
rvsvbase
vaccin
report
elicit
effect
humor
cellular
immun
respons
well
protect
periexposur
herein
test
protect
efficaci
three
rvsv
express
either
nucleoprotein
n
f
g
malaysian
strain
niv
follow
singl
dose
vaccin
vector
express
g
f
fulli
protect
syrian
hamster
lethal
niv
challeng
wherea
n
express
vector
confer
partial
protect
use
passiv
serum
transfer
determin
full
protect
confer
glycoprotein
f
g
specif
antibodi
like
neutral
fraction
elicit
rvsv
vaccin
howev
compon
immun
system
cellular
respons
also
contribut
protect
demonstr
partial
efficaci
lack
protect
passiv
transfer
studi
case
n
express
vaccin
vector
vero
cell
european
collect
cell
cultur
salisburi
uk
babi
hamster
kidney
cell
express
bacteriophag
promot
kindli
provid
dr
naoto
ito
gifu
univers
japan
use
niv
malaysian
strain
kindli
provid
special
pathogen
branch
center
diseas
control
prevent
atlanta
propag
previous
describ
plasmid
kindli
provid
j
rose
yale
univers
new
modifi
previous
describ
encod
open
read
frame
orf
zair
ebolaviru
zebov
glycoprotein
gp
place
encod
vsv
glycoprotein
g
niv
f
g
n
orf
malaysian
strain
niv
amplifi
similarli
clone
downstream
zebovgp
fig
cell
transfect
use
transfect
reagent
miru
madison
wi
along
individu
plasmid
encod
vsv
n
p
l
orf
modifi
vsv
genom
plasmid
shown
fig
cell
incub
day
time
supernat
collect
passag
fresh
vero
cell
cultur
monitor
daili
cytopathogen
effect
cpe
supernat
cell
collect
sequenc
confirm
analysi
protein
express
rescu
virus
refer
rvsvzebovgpnivf
rvsvzebovgpnivg
rvsvzebovgpnivn
vero
cell
infect
differ
rvsv
multipl
infect
moi
two
day
later
cell
cultur
supernat
collect
centrifug
result
pellet
subject
sdspolyacrylamid
gel
electrophoresi
protein
transfer
pvdf
membran
ge
healthcar
uk
zebovgp
detect
use
monoclon
antibodi
kindli
provid
takada
hokkaido
univers
sapporo
japan
flow
cytometri
perform
detect
niv
f
g
n
express
virusinfect
vero
cell
h
post
infect
collect
wash
pb
contain
mm
edta
surfac
stain
cell
incub
primari
antibodi
antig
antif
kindli
provid
hector
aguilarcarreno
washington
state
univers
usa
follow
incub
goat
antirabbit
antibodi
conjug
alexa
life
technolog
fix
paraformaldehyd
pfa
intracellular
stain
cell
fix
pfa
min
wash
incub
buffer
contain
saponin
sigma
min
permeabil
cell
incub
antiniv
n
rabbit
antiserum
kindli
provid
wang
csiro
livestock
industri
geelong
australia
follow
mention
goat
antirabbit
antibodi
presenc
saponin
flow
cytometri
perform
use
lsr
ii
bd
bioscienc
san
jose
ca
data
analyz
use
flowjo
softwar
treestar
inc
ashland
measur
fusogen
activ
express
niv
f
g
vero
cell
grown
plate
infect
individu
rvsv
coinfect
rvsvzebovgpnivf
rvsvzebovgpnivg
h
moi
day
cell
stain
fix
kwik
diff
kit
thermo
scientif
group
week
old
syrian
hamster
harlan
indianapoli
vaccin
intraperiton
ip
plaqu
form
unit
pfu
specifi
rvsv
vector
mockvaccin
dmem
total
volum
two
day
prior
niv
challeng
day
post
vaccin
blood
collect
retroorbit
bleed
analysi
antibodi
respons
day
anim
challeng
ip
ld
tcid
niv
monitor
clinic
sign
diseas
necropsi
perform
four
anim
group
day
post
challeng
measur
viral
load
attempt
viru
isol
assess
histopatholog
brain
lung
spleen
tissu
collect
place
rlt
lysi
buffer
qiagen
valencia
ca
rna
extract
formalin
histopatholog
immunohistochemistri
ihc
analysi
remain
six
anim
use
monitor
surviv
day
post
challeng
antibodi
respons
measur
enzymelink
immunosorb
assay
elisa
describ
previous
neutral
titer
determin
neutral
tissu
cultur
infect
dose
ntcid
assay
hamster
tissu
collect
process
describ
previous
embed
tissu
section
stain
hematoxylin
eosin
h
e
mention
antiniv
n
rabbit
antiserum
dilut
immunohistochemistri
ihc
tissu
process
qrtpcr
describ
previous
target
niv
n
defin
dilut
niv
rna
use
triplic
gener
standard
curv
sampl
tcid
equival
extrapol
niv
isol
titrat
perform
previous
describ
similar
method
use
qrtpcr
assay
target
vsv
n
fwd
primer
cggaggattgacgactaatgc
rev
primer
cgagccattcgaccacatc
probe
famcgc
cac
aag
gca
gmgb
group
week
old
hamster
vaccin
ip
pfu
specifi
rvsv
vaccin
vector
day
anim
exsanguin
via
cardiac
punctur
serum
inactiv
gammairradi
mrad
measur
antibodi
titer
elisa
ntcid
assay
describ
posit
sera
pool
group
group
six
hamster
given
ml
serum
ip
day
prior
day
post
ip
challeng
ld
tcid
niv
monitor
clinic
sign
day
work
niv
complet
facil
rocki
mountain
laboratori
niaid
nih
standard
oper
procedur
approv
institut
biosafeti
committe
anim
experi
approv
institut
anim
care
use
committe
perform
follow
guidelin
associ
assess
accredit
laboratori
anim
care
intern
aaalac
certifi
staff
aaalacapprov
facil
gener
rvsv
express
niv
protein
f
g
n
orf
amplifi
individu
insert
downstream
zebovgp
gene
previous
describ
fig
individu
genom
construct
transfect
togeth
vsv
helper
plasmid
cell
supernat
passag
onto
fresh
vero
cell
cultur
demonstr
cpe
verifi
viral
protein
express
use
western
blot
whole
cell
lysat
detect
zebovgp
flow
cytometri
detect
niv
f
g
cell
surfac
niv
n
intracellular
three
rescu
rvsv
express
zebovgp
individu
virus
also
express
either
niv
f
g
n
fig
verifi
structur
function
integr
surfac
express
niv
f
g
fusogen
activ
test
coinfect
monolay
vero
cell
rvsvzebovgpnivf
rvsvzebovgpnivg
observ
largescal
celltocel
fusion
result
multinucl
syncytia
format
phenomenon
requir
presenc
function
niv
f
g
cell
surfac
fig
humor
immun
respons
vaccin
assess
syrian
hamster
wellestablish
niv
anim
diseas
model
group
hamster
immun
singl
ip
dose
pfu
differ
rvsv
vector
rvsvzebovgpnivf
rvsvzebovgpnivg
rvsvzebovgpnivn
rvsvzebovgp
control
day
blood
sampl
obtain
test
nivspecif
antibodi
elisa
use
antigen
prepar
whole
inactiv
niv
particl
contrast
anim
control
group
rvsvzebovgp
vaccin
anim
show
high
level
antibodi
titer
rang
tabl
addit
test
sera
presenc
neutral
antibodi
niv
expect
vaccin
hamster
rvsvzebovgp
rvsvzebovgpnivn
result
gener
neutral
antibodi
tabl
contrast
anim
group
vaccin
rvsvzebovgpnivf
rvsvzebovgpnivg
gener
neutral
antibodi
titer
rang
tabl
anim
per
group
immun
respons
studi
subsequ
challeng
ip
ld
niv
protect
studi
ad
group
six
hamster
mockvaccin
dmem
six
anim
group
monitor
surviv
anim
control
group
dmem
rvsvzebovgp
develop
clinic
sign
diseas
day
post
challeng
result
respiratori
distress
vari
degre
neurolog
dysfunct
euthan
accord
approv
protocol
fig
anim
group
vaccin
rvsvzebovgpnivf
rvsvzebovgpnivg
complet
protect
clinic
diseas
signific
weight
loss
fig
b
hamster
vaccin
rvsvzebovgpnivn
partial
protect
two
six
anim
clinic
sign
diseas
remain
four
anim
euthan
day
post
challeng
fig
b
order
determin
impact
vaccin
viru
replic
collect
brain
lung
spleen
tissu
day
post
niv
challeng
four
hamster
group
describ
niv
load
determin
isol
viral
load
determin
use
niv
nspecif
qrtpcr
assay
fig
nivvaccin
anim
lower
organ
level
viral
rna
compar
anim
control
group
tcid
equivalentmg
tissu
rvsvzebovgpnivf
rvsvzebovgpnivg
vaccin
anim
show
organ
load
tcid
equivalentmg
tissu
rvsvzebovgpnivn
vaccin
anim
show
greater
reduct
viral
organ
load
compar
rvsvzebovgp
vaccin
control
order
confirm
posit
immunohistochemistri
describ
fig
repres
replic
challeng
viru
niv
rather
n
express
vaccin
vector
rvsvzebovgpnivn
perform
vsv
nspecif
qrtpcr
assay
vsv
n
rna
could
detect
lung
tissu
rvsvzebovgpnivn
vaccin
anim
niv
isol
success
control
anim
rvsvzebovgp
group
stain
histolog
analysi
perform
lung
tissu
deriv
anim
euthan
day
post
challeng
rvsvzebovgp
vaccin
control
anim
develop
multifoc
interstiti
pneumonia
character
thicken
alveolar
septa
small
moder
number
macrophag
fewer
neutrophil
congest
fibrin
edema
fig
occasion
small
number
inflammatori
cell
fibrin
edema
fill
adjac
alveolar
space
also
multifoc
pleural
mesotheli
hyperplasia
alveolar
arteriolar
endotheli
cell
pulmonari
arteriolar
smooth
muscl
cell
demonstr
diffus
viral
antigen
ihc
stain
fig
anim
three
four
partial
protect
rvsvzebovgpnivn
group
develop
pneumonia
similar
found
control
hamster
rare
weak
multifoc
viral
antigen
stain
primarili
within
mononuclear
cell
area
pneumonia
anim
complet
protect
group
rvsvzebovgpnivf
rvsvzebovgpnivg
show
lesion
neg
viral
antigen
ihc
stain
fig
test
whether
antibodi
elicit
rvsv
vector
alon
afford
protect
niv
challeng
perform
passiv
transfer
experi
group
hamster
vaccin
pfu
ip
one
rvsv
vector
day
sera
collect
pool
group
pool
sera
rvsvzebovgpnivf
rvsvzebovgpnivg
neutral
titer
respect
wherea
sera
collect
rvsvzebovgp
rvsvzebovgpnivn
vaccin
group
neg
group
six
hamster
administ
ip
ml
pool
serum
day
prior
day
follow
niv
challeng
ld
anim
except
one
receiv
serum
without
neutral
activ
rvsvzebovgp
rvsvzebovgpnivn
euthan
accord
protocol
fig
anim
receiv
serum
display
neutral
activ
rvsvzebovgpnivfor
rvsvzebovgpnivg
complet
protect
niv
challeng
sign
diseas
past
decad
multipl
distinct
niv
vaccin
approach
develop
evalu
differ
anim
model
includ
dna
vaccin
subunit
vaccin
viruslik
particl
solubl
g
protein
replicationdefici
vector
well
replicationcompet
vector
sever
approach
evalu
abil
elicit
immun
respons
wherea
other
use
evalu
protect
efficaci
niv
challeng
differ
anim
model
except
three
recent
studi
vaccin
approach
thu
far
requir
boost
immun
scheme
immunogen
andor
efficaci
therefor
less
like
use
ring
vaccin
approach
outbreak
situat
three
new
studi
includ
adenovirusassoci
viru
vector
express
niv
g
replicationincompet
vsv
pseudotyp
express
niv
g
f
protein
vsv
virion
f
g
undergo
singl
round
replic
produc
coinfect
two
vsv
pseudotyp
one
express
f
one
express
g
adenovirusassoci
viru
vector
approach
use
rel
high
vaccin
dose
vsv
approach
base
replicationdefici
pseudotyp
particl
produc
plasmid
transfect
may
challeng
regard
vaccin
product
goal
develop
fastact
singledos
niv
vaccin
suitabl
use
ring
vaccin
approach
outbreak
current
occur
bangladesh
chose
liveattenu
rvsv
vector
platform
due
eas
genet
modif
subsequ
effici
costeffect
manufactur
prefer
replicationcompet
vaccin
gener
provid
better
durabl
compar
replicationincompet
vaccin
approach
elicit
faster
effect
innat
adapt
immun
respons
replicationcompet
vaccin
approach
howev
commonli
associ
safeti
concern
previou
vaccin
work
use
rvsv
platform
includ
immun
sever
immunecompromis
anim
speci
assign
approach
good
safeti
record
noteworthi
liveattenu
rvsvbase
vaccin
vector
approv
use
human
laboratori
exposur
ebola
viru
among
commonli
use
replic
vaccin
vector
vsv
provid
advantag
similar
platform
limit
preexist
immun
vsv
human
popul
rare
mild
human
diseas
caus
vsv
larg
anim
pathogen
limit
vsv
immun
pathogen
remov
vsvg
major
target
neutral
antibodi
key
vsv
virul
factor
vsvg
replac
vaccin
vector
zebovgp
overcom
lack
function
surfac
protein
viru
entri
viru
entri
achiev
chosen
niv
antigen
henipaviru
cell
entri
depend
presenc
g
f
protein
zebovgp
particularli
chosen
known
target
import
immun
cell
mononuclear
phagocytot
antigen
present
cell
target
cell
allow
strong
stimul
better
antigen
present
mhc
class
ii
pathway
thu
lead
potent
innat
adapt
immun
respons
order
character
mechan
protect
afford
rvsvbase
vaccin
vector
examin
import
humor
immun
respons
previous
demonstr
protect
niv
challeng
afford
passiv
serum
transfer
contain
neutral
antibodi
addit
human
neutral
monoclon
antibodi
protect
niv
hendra
viru
sever
anim
model
rvsv
vaccin
vector
express
niv
f
g
induc
glycoproteinspecif
antibodi
respons
confer
complet
protect
niv
challeng
serum
transfer
studi
neutral
antibodi
respons
like
key
protect
serum
transfer
nspecif
antibodi
show
protect
effect
even
though
role
nonneutr
glycoproteinspecif
antibodi
protect
exclud
vsv
known
also
elicit
strong
cellular
immun
respons
role
cellular
immun
respons
mediat
rvsv
vector
support
partial
protect
achiev
vaccin
rvsv
vector
express
niv
n
well
lack
protect
serum
transfer
experi
use
sera
nspecif
nonneutr
antibodi
therefor
new
rvsv
vector
might
stronger
vaccin
candid
vaccin
platform
select
trigger
humor
immun
respons
subunit
protein
vaccin
describ
vaccin
approach
mechan
protect
could
use
control
niv
infect
spread
outbreak
situat
use
ring
vaccin
approach
recent
outbreak
involv
increas
humantohuman
transmiss
event
often
seen
famili
member
healthcar
worker
due
eas
identifi
highrisk
individu
close
contact
patient
fastact
singledos
vaccin
like
rvsv
vector
would
advantag
target
use
outbreak
vaccin
need
multipl
inject
thu
requir
time
vaccin
protect
anoth
advantag
replicationcompet
rvsv
efficaci
upon
use
periexposur
allow
simultan
vaccin
treatment
outbreak
situat
futur
studi
aim
assess
time
immun
periexposur
treatment
efficaci
new
rvsv
niv
vector
well
efficaci
studi
second
anim
model
fulfil
fda
requir
licens
tissu
brain
spleen
lung
collect
rlt
buffer
four
anim
per
group
day
challeng
homogen
prior
total
rna
extract
quantit
rtpcr
use
nspecif
primer
probe
set
use
determin
tcid
equival
extrapol
standard
curv
niv
seed
stock
known
titer
individu
anim
repres
dot
horizont
line
repres
mean
error
bar
indic
standard
error
mean
sem
serum
collect
group
hamster
day
vaccin
pfu
specif
vaccin
vector
one
day
prior
day
post
challeng
ld
niv
group
six
hamster
given
ml
sera
immun
anim
monitor
day
sign
diseas
humor
immun
respons
foreign
protein
day
rvsv
vaccin
measur
elisa
whole
inactiv
niv
particl
antigen
ntcid
assay
live
nipah
viru
